With increasing specialty drug costs, pharmacy benefit managers,health plans and industry experts often tout the use of biosimilarsas a strategy to lower cost. In 2013,
The news that the FDA approved the first A-rated (meaning that pharmacists may freely substitute it without physician approval) generic form of Advair Diskus on
The FDA has released a welcome new policy guidance document surrounding compounded drugs that will equip PBMs and Carriers with some much needed objective standards